Kei Sakamoto
Has open position
Professor at University of Copenhagen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Professor Kei Sakamoto is a faculty member at the University of Copenhagen, Denmark. His research focuses on cardiometabolic innovation and cellular mechanisms, particularly involving AMPK and related metabolic pathways. Recent publications include studies on the inhibition of AMPK, the role of Pellino 3 E3 Ligase in autophagy, and advancements in quantifying persulfidation on proteins. He is dedicated to understanding and developing novel therapeutic strategies related to metabolism and cellular function.
Positions (5)
Kei Sakamoto
University of Copenhagen
Posted Yesterday
The University of Copenhagen is recruiting a full-time postdoctoral researcher to join Professor Kei Sakamoto’s group at the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR). The position focuses on molecular and metabolic modulators of AMP-activated protein kinase (AMPK) signaling and glucose regulation, with an emphasis on skeletal muscle and cardiometabolic disease. AMPK is a central regulator of cellular and whole-body energy homeostasis. The project will investigate novel molecules and innovative approaches for modulating AMPK signaling, and assess their therapeutic potential for diseases such as type 2 diabetes and fatty liver disease. The research aims to connect fundamental discoveries in energy sensing and metabolic control with translational drug-discovery opportunities. The Sakamoto Group studies the molecular mechanisms that govern cellular energy sensing and metabolic homeostasis. Its work examines reversible phosphorylation, allosteric regulation of signaling proteins and metabolic enzymes, and the ways disruption of these processes contributes to cardiometabolic disease. The successful researcher will contribute to a multidisciplinary programme spanning metabolic signaling, computational chemistry, in vivo physiology and pharmacology, and molecular and cellular biology. CBMR is an interdisciplinary academic research centre within the Faculty of Health and Medical Sciences. Its approximately 260 employees work in an international and collaborative environment that combines genetics, physiology and pharmacology, from single-cell genomics to whole-body systems. The centre is located in the Maersk Tower at Panum in Copenhagen and supports collaboration, early-career training and professional development. The role offers an opportunity to develop innovative therapeutic strategies while working across fundamental molecular biomedicine, pharmacology and translational cardiometabolic research.
Posted Yesterday
University of Copenhagen
University of Copenhagen
2 days ago
The University of Copenhagen is recruiting a postdoctoral researcher for the Sakamoto Group at the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR). The project focuses on AMP-activated protein kinase (AMPK), a central regulator of cellular and whole-body energy homeostasis, and its potential as a therapeutic target in cardiometabolic disease. The researcher will identify innovative molecular modalities for modulating AMPK signaling, with particular emphasis on skeletal muscle, and investigate their therapeutic potential for conditions including type 2 diabetes and fatty liver disease. The work combines fundamental biological discovery with drug development and translational research. The Sakamoto Group studies the molecular mechanisms governing cellular energy sensing and metabolic homeostasis. Its research examines reversible phosphorylation, allosteric regulation of signaling proteins and metabolic enzymes, and the way disruptions in these processes contribute to cardiometabolic disease. The group aims to identify therapeutic targets and develop small-molecule or peptide-based modulators capable of restoring energy balance. The postdoctoral researcher will work in a collaborative, interdisciplinary environment integrating metabolic signaling, computational chemistry, in vivo physiology and pharmacology, and molecular and cellular biology. CBMR provides an international research setting with collaboration across genetics, physiology and pharmacology, together with opportunities for scientific training and professional development. The position is based at the CBMR in the Maersk Tower at Panum, University of Copenhagen.
2 days ago
Kei Sakamoto
University of Copenhagen
1 month ago
University of Copenhagen is advertising a Researcher position in the molecular and physiological regulation of muscle glycogen degradation at the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) , Maersk Tower, Panum Institute, Copenhagen, Denmark. The project is hosted in the Sakamoto Group and focuses on skeletal muscle physiology , exercise metabolism , glycogen metabolism , enzyme kinetics , and stable isotope tracer methods. The work uses novel genetic preclinical models, including point mutations affecting glycogen phosphorylase regulation and muscle-specific deletion of glycogen synthase, to study how allosteric ligands, phosphorylation, and muscle glycogen content control glycogen breakdown and substrate utilization. The successful candidate will carry out major biochemical and physiological analyses, including in vitro kinetics of wild-type and mutant enzymes, in situ and ex vivo muscle analyses, whole-body metabolic phenotyping in transgenic mouse models, and in vivo substrate utilization and nutrient flux measurements during and after exercise. The role also includes coordination with collaborators and supervision of students and researchers. Eligibility highlights: PhD in molecular and cellular biology, biochemistry, cell signaling, physiology, or a related field; at least four years of postdoctoral experience; strong hands-on experience in protein biochemistry, skeletal muscle metabolism, rodent preclinical studies, exercise modalities, and stable isotope tracer work; FELASA certification or similar; strong project management, teaching, and supervision experience; excellent English communication. Employment terms: full-time, fixed-term for 2 years, starting 1 January 2027 or by agreement. Salary and pension follow the Danish AC agreement, with possible supplement depending on qualifications. Application deadline: 1 October 2026, 23:59 CET. Apply online in English and upload a motivation letter, CV, certified/signed PhD certificate, and publication list as PDFs.
1 month ago
University of Copenhagen
University of Copenhagen
5 months ago
CBMR International PhD and Postdoc Program at the University of Copenhagen is recruiting for PhD and postdoc projects starting in late 2026, with a start date of November 15, 2026 . The program is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) and supports competitive national and international recruitment of early-career researchers. The research environment is centered on basic metabolic research , cardiometabolic research , and translational work relevant to human pathophysiology . Projects highlighted in the post span several interconnected themes, including obesity , type 2 diabetes , skeletal muscle biology , glucose homeostasis , AMPK signaling , multi-omics , microbiome science , liver disease , and digital biomarkers . Supervisors named in the announcement include Juleen R. Zierath , Jonas T. Treebak , Zach Gerhart-Hines , Torben Hansen , Kei Sakamoto , and Tune H. Pers . The fellowship package includes salary and running costs for four years for PhD fellows and three years for postdoc fellows. The post emphasizes a collaborative, interdisciplinary setting with access to CBMR platforms and international research networks. Eligibility is aimed at candidates with a basic science background or clinical training who want to pursue academic medicine. The announcement does not specify a deadline in the text provided, but it states that the next round of applications has opened . Interested applicants should review the CBMR fellowship page, identify a suitable project, and apply through the program’s application link.
5 months ago
Muhammad Qasim
University of Copenhagen
5 months ago
CBMR International PhD and Postdoc Program at the University of Copenhagen is recruiting for PhD and postdoctoral projects starting in late 2026, with positions beginning on 2026-11-15 . The program is hosted by the Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR) and supports competitive national and international recruitment. The opportunity is centered on basic cardiometabolic research , human pathophysiology , and integrative research approaches . The listed projects span topics such as skeletal muscle metabolism , continuous glucose monitoring , obesity therapeutics , oral-liver axis , multi-omics , AMPK signaling , microbiome science , liver disease , and energy expenditure . Candidates may work with in vivo models, clinical cohorts, transcriptomics, proteomics, genetics, bioinformatics, computational chemistry, and physiological phenotyping. The program is aimed at early career researchers with a basic science background or clinicians who want a career in academic medicine . Each PhD fellow receives a competitive package including salary and running costs for four years , and each postdoc fellow receives a competitive package including salary and running costs for three years . Applications are now open. Interested candidates should review the project descriptions on the CBMR fellowship page and apply through the official application links for the project that best matches their expertise and research interests.
5 months ago
Articles (28)
Year:
2025
Nutrient deprivation is a major trigger of autophagy, a conserved quality control and recycling process essential for cellular and tissue homeostasis. In a high-content image-based screen of the human ubiquitome, we here identify the E3 ligase Pellino 3 (PELI3) as a crucial regulator of starvation-induced autophagy. Mechanistically, PELI3 localizes to autophagic membranes, where it interacts with the ATG8 proteins through an LC3-interacting region (LIR). This facilitates PELI3-mediated ubiquitination of ULK1, driving ULK1’s subsequent proteasomal degradation. PELI3 depletion leads to an aberrant accumulation and mislocalization of ULK1 and disrupts the early steps of autophagosome formation. Genetic deletion of Peli3 in mice impairs fasting-induced autophagy in the liver and enhances starvation-induced hepatic steatosis by reducing autophagy-mediated clearance of lipid droplets. Notably, PELI3 expression is decreased in the livers of patients with metabolic dysfunction–associated steatotic liver disease (MASLD), suggesting its role in hepatic steatosis development in humans. The findings suggest that PELI3-mediated control of autophagy plays a protective role in liver health.
Year:
2025
Inhibition of adenosine 5′-monophosphate (AMP)–activated protein kinase (AMPK) is under increasing investigation for its therapeutic potential in many diseases. Existing AMPK inhibitors are however limited, with poor selectivity and substantial off-target effects. Here, we provide mechanistic insights and describe the cellular selectivity of the recently identified AMPK inhibitor BAY-3827. A 2.5-Å cocrystal structure of the AMPK kinase domain with BAY-3827 revealed distinct features including a disulfide bridge between the αD helix Cys 106 and the activation loop residue Cys 174 . This bridge appears to stabilize the activation loop such that Asn 162 repositions the Asp-Phe-Gly (DFG) motif Phe 158 toward the C-terminal lobe, displacing His 137 and disrupting the regulatory spine, promoting an inactive kinase state. In hepatocytes, BAY-3827 blocked AMPK activator (MK-8722)–mediated phosphorylation of ACC1 and corresponding inhibition of lipogenesis. Transcriptome analysis revealed that BAY-3827 down-regulated ~30% of MK-8722–stimulated AMPK-dependent genes. We establish the molecular and cellular basis of BAY-3827’s selectivity and utility for delineating AMPK functions while highlighting its limitations.
Year:
2025
Inhibition of AMP-activated protein kinase (AMPK) is under increasing investigation for its therapeutic potential in many diseases, including certain cancers. However, existing AMPK- inhibitors available as tool compounds are largely limited to compound C/dorsomorphin and SBI-0206965, both of which suffer from poor selectivity and off-target effects. Here we describe the structure-based molecular insights and cellular actions of a recently identified potent AMPK inhibitor, BAY-3827. Kinase selectivity profiling and sequence analyses of kinases that are highly or weakly inhibited by BAY-3827 uncovered key conserved residues involved in its inhibitory mechanism. A 2.5 Å co-crystal structure of the AMPK kinase domain (KD)-BAY-3827 complex and comparison with known KD-inhibitor structures, revealed an overlapping site in the ATP-binding pocket and an αC helix-out conformation. A distinct feature of the BAY-3827-bound state is the formation of a disulfide bridge between the αD helix Cys 106 and the activation loop residue Cys 174 . This bridge appears to stabilize the activation loop such that Asn 162 repositions the DFG motif Phe 158 toward the C-terminal kinase lobe, displacing His 137 and disrupting the regulatory spine, thereby promoting an inactive state. In hepatocytes, 2.5-5 μM BAY-3827, but not the structurally resembling inactive BAY-974, fully blocked AMPK activator (MK-8722)-mediated phosphorylation of ACC1 and corresponding inhibition of lipogenesis. Unbiased transcriptome analysis in MK- 8722-treated wild-type and AMPK-null hepatocytes revealed that 5 μM BAY-3827 downregulated >30% of MK-8722-stimulated AMPK-dependent genes. Based on its greater selectivity and potency substantiated by comprehensive structural and cellular investigations, BAY-3827 is a powerful tool to delineate AMPK functions. One-sentence summary We provide the mechanism of action of the potent and selective AMPK inhibitor BAY-3827, which blocks AMPK-dependent cellular functions.
Year:
2025
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
Year:
2025
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo . Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
Year:
2025
Fibrolamellar carcinoma (FLC) is a liver cancer of adolescents and young adults characterized by fusions of the genes encoding the protein kinase A catalytic subunit, PRKACA, and heat shock protein, DNAJB1. The chimeric DNAJB1-PRKACA protein has increased kinase activity and is essential for FLC xenograft growth. Here, we explore the critical oncogenic pathways controlled by DNAJB1-PRKACA using patient-derived FLC models, engineered systems, and patient samples. We show that a core function of DNAJB1-PRKACA is the phosphorylation and inactivation of salt-inducible kinases (SIKs). This leads to deregulation of the CRTC2 transcriptional coactivator and p300 acetyltransferase, resulting in transcriptional reprogramming and increased global histone acetylation, driving malignant growth. Our studies establish a central oncogenic mechanism of DNAJB1-PRKACA and suggest the potential of targeting CRTC2/p300 in FLC. Notably, these findings link this rare cancer’s signature fusion oncoprotein to more common cancer gene alterations involving STK11 and GNAS, which also function via SIK suppression. Significance: This work combines functional studies in model systems and examination of human tumor specimens to define a central oncogenic pathway driven by DNAJB1-PRKACA fusions in FLC. DNAJB1-PRKACA-mediated inactivation of the SIK stimulates CRTC2-p300-mediated transcription to drive tumor growth. The findings illuminate pathogenic mechanisms and inform therapeutic development.
Year:
2025
Supplementary Table S1. List of SsTOP genes Supplementary Table S2. List of SsTOP (-E2F) genes Supplementary Table S3A. TF activity DMSO vs PKAi Supplementary Table S3B. TF activity PKAi+SIKi (COMBO) vs PKAi Supplementary Table S3A. CRTC2 targets gene set Supplementary Table S4. Curated FLC gene sets Supplementary Table S5. Expression of amino acid metabolism/urea cycle genes in FLC Supplementary Table S6. Regulation of curated FLC pathways by PKAi and SIKi in FLX1 Supplementary Table S7. MSigDB (Human) Hallark_E2F targets gene set
Year:
2025
Supplementary Figure S1: Validation of the specificity of the p-SIK Ser343 antibody. Supplementary Figure S2. PKAfus inactivates SIKs to support tumor cell growth in vitro and in vivo . Supplementary Figure S3. PKAfus reprograms transcription by inactivating SIK and stimulating CRTC2. Supplementary Figure S4. CRTC2/CREB mediates transcriptional regulation downstream of PKAfu. Supplementary Figure S5. CRTC2/CREB supports tumor cell growth downstream of PKAfus. Supplementary Figure S6. Primary FLC tumors show deregulation of SIK/CRTC2- controlled genes. Supplementary Figure S7. PKAfus driven tumors are sensitive to p300 inhibition. Supplementary Figure S8. PKAfus driven tumors are sensitive to p300 inhibition.
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Collaborators (36)
Daniel Rader
Chair
University of Pennsylvania
Christoffer Clemmensen
Associate Professor
Københavns Universitet
Robert Manguso
Associate Professor
Harvard Medical School
Tenna Holgersen Bryde
Københavns Universitet
Emily Day
Assistant Professor
University of Western Ontario
Taran Gujral
Professor
Fred Hutchinson Cancer Research Center
Marc Wein
Associate Professor of Medicine
Massachusetts General Hospital
Lisa Frankel
Associate Professor
University of Copenhagen
Olga Göransson
-
Aida Martinez-Sanchez
Imperial College London
Anders Lund
Director, Professor
University of Copenhagen Biotech Research and Innovation Centre
Juleen Zierath
Københavns Universitet
John Scott
Director, Dark Kinase Drug Discovery Lab
Monash Institute of Pharmaceutical Sciences
Tor Erik Rusten
assistant Professor
University of Oslo
Pascal Maire
INSERM
Neil Ranson
Professor
University of Leeds
Monika Lewinska
Assistant professor
University of Copenhagen Biotech Research and Innovation Centre
Béatrice Choi
Assistant Professor
Københavns Universitet
David A. Jacobson
Professor
Vanderbilt University
Alice Pollard
Imperial College London
John D. Gordan
University of California
jun qi
Assistant Professor
Dana-Farber Cancer Institute
Meng-Ju Wu
Assistant Professor
University of Massachusetts Chan Medical School
Elton Zeqiraj
Wellcome Trust Senior Research Fellow and Professor of Structural Biology
University of Leeds
Kate Townsend Creasy
Assistant Professor
University of Pennsylvania
Zachary Gerhart-Hines
Københavns Universitet
David Liu
Assistant Professor
Dana-Farber Cancer Institute
Carsten Jörn Beese
Leibniz-Forschungsinstitut für Molekulare Pharmakologie
Mark A Febbraio
MONASH UNIVERSITY
Won Dong Lee
Assistant Professor
Yonsei University
Alex Addinsall
Københavns Universitet
Matthieu Dos Santos
Assistant Professor, Investigator Track
Washington University in St. Louis
Conchita Fraguas Bringas
Københavns Universitet
Jon Oakhill
Group Head
St Vincent's Institute of Medical Research
Dipsikha Biswas
Københavns Universitet
Sandra Galic
St Vincent's Institute of Medical Research
Make your next move.
Prepare your application
Review drafts before you send them.